Research ArticleSystemic Lupus Erythematosus

Comorbidity Development and Mortality During 10 Years of Follow-up in a Danish Nationwide Cohort of 3178 Patients With Systemic Lupus Erythematosus

Renata Baronaite Hansen, Mikkel Faurschou and Søren Jacobsen
The Journal of Rheumatology February 2026, 53 (2) 170-179; DOI: https://doi.org/10.3899/jrheum.2025-0015

REFERENCES

  1. 1.↵
    1. Moghaddam B,
    2. Marozoff S,
    3. Li L,
    4. Sayre EC,
    5. Zubieta JAA.
    All-cause and cause-specific mortality in systemic lupus erythematosus: a population-based study. Rheumatology 2021;61:367-76.
    OpenUrlPubMed
  2. 2.↵
    1. Barber MRW,
    2. Drenkard C,
    3. Falasinnu T, et al.
    Global epidemiology of systemic lupus erythematosus. Nat Rev Rheumatol 2021; 17:515-32.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Kuo CF,
    2. Chou IJ,
    3. Rees F, et al.
    Temporal relationships between systemic lupus erythematosus and comorbidities. Rheumatology 2019;58:840-8.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Schmidt M,
    2. Schmidt SAJ,
    3. Adelborg K, et al.
    The Danish health care system and epidemiological research: from health care contacts to database records. Clin Epidemiol 2019;11:563-91.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Hermansen MLF,
    2. Lindhardsen J,
    3. Torp-Pedersen C,
    4. Faurschou M,
    5. Jacobsen S.
    Incidence of systemic lupus erythematosus and lupus nephritis in Denmark: a nationwide cohort study. J Rheumatol 2016;43:1335-9.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    1. Baronaite Hansen R,
    2. Jacobsen S.
    Infections increase risk of arterial and venous thromboses in Danish patients with systemic lupus erythematosus: 5102 patient-years of followup. J Rheumatol 2014;41:1817-22.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Charlson ME,
    2. Pompei P,
    3. Ales KL,
    4. MacKenzie CR.
    A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Elixhauser A,
    2. Steiner C,
    3. Harris DR,
    4. Coffey RM.
    Comorbidity measures for use with administrative data. Med Care 1998;36:8-27.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Gladman D,
    2. Ginzler E,
    3. Goldsmith C, et al.
    The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 1996;39:363-9.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Quan H,
    2. Sundararajan V,
    3. Halfon P, et al.
    Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005;43:1130-9.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Hansen RB,
    2. Simard JF,
    3. Faurschou M,
    4. Jacobsen S.
    Distinct patterns of comorbidity prior to diagnosis of incident systemic lupus erythematosus in the Danish population. J Autoimmun 2021;123:102692.
    OpenUrlPubMed
  12. 12.↵
    1. Jönsen A,
    2. Clarke AE,
    3. Joseph L, et al.
    Association of the Charlson comorbidity index with mortality in systemic lupus erythematosus. Arthritis Care Res 2011;63:1233-7.
    OpenUrlCrossRef
  13. 13.
    1. Albrecht K,
    2. Redeker I,
    3. Aringer M,
    4. Marschall U,
    5. Strangfeld A,
    6. Callhoff J.
    Comorbidity and healthcare utilisation in persons with incident systemic lupus erythematosus followed for 3 years after diagnosis: analysis of a claims data cohort. Lupus Sci Med 2021;8:e000526.
    OpenUrlAbstract/FREE Full Text
  14. 14.
    1. Yu CY,
    2. Kuo CF,
    3. Chou IJ, et al.
    Comorbidities of systemic lupus erythematosus prior to and following diagnosis in different age-at-onset groups. Lupus 2022;31:963-73.
    OpenUrlPubMed
  15. 15.↵
    1. Ward MM.
    Development and testing of a systemic lupus-specific risk adjustment index for in-hospital mortality. J Rheumatol 2000;27:1408-13.
    OpenUrlPubMed
  16. 16.↵
    1. Krumholz HM.
    Registries and selection bias: the need for accountability. Circ Cardiovasc Qual Outcomes 2009;2:517-8.
    OpenUrlFREE Full Text
  17. 17.↵
    1. Arbuckle MR,
    2. McClain MT,
    3. Rubertone MV, et al.
    Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003;349:1526-33.
    OpenUrlCrossRefPubMed
  18. 18.↵
    1. Durcan L,
    2. O’Dwyer T,
    3. Petri M.
    Management strategies and future directions for systemic lupus erythematosus in adults. Lancet 2019;393:2332-43.
    OpenUrlCrossRefPubMed
  19. 19.↵
    1. Arnaud L,
    2. Tektonidou MG.
    Long-term outcomes in systemic lupus erythematosus: trends over time and major contributors. Rheumatology 2020;59 Suppl 5:v29-38.
    OpenUrlPubMed
  20. 20.↵
    1. Bruce IN,
    2. O’Keeffe AG,
    3. Farewell V, et al.
    Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. Ann Rheum Dis 2015;74:1706-13.
    OpenUrlAbstract/FREE Full Text
  21. 21.↵
    1. Timlin H,
    2. Petri M.
    Transient ischemic attack and stroke in systemic lupus erythematosus. Lupus 2013;22:1251-8.
    OpenUrlCrossRefPubMed
  22. 22.↵
    1. Tselios K,
    2. Gladman DD,
    3. Su J,
    4. Ace O,
    5. Urowitz MB.
    Evolution of risk factors for atherosclerotic cardiovascular events in systemic lupus erythematosus: a longterm prospective study. J Rheumatol 2017;44:1841-9.
    OpenUrlAbstract/FREE Full Text
  23. 23.↵
    1. World Health Organization
    Assessed on June 8, 2024. World Health Organization. [Internet. Accessed November 17, 2025.] Available from: https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death
  24. 24.↵
    1. Manadan AM,
    2. Kambhatla S,
    3. Gauto-Mariotti E,
    4. Okoli C,
    5. Block JA.
    Reasons for hospitalization and in-hospital mortality in adult systemic lupus erythematosus. ACR Open Rheumatol 2020; 2:683-9.
    OpenUrlPubMed
  25. 25.↵
    1. Yafasova A,
    2. Fosbøl EL,
    3. Schou M, et al.
    Long-term cardiovascular outcomes in systemic lupus erythematosus. J Am Coll Cardiol 2021;77:1717-27.
    OpenUrlPubMed
  26. 26.↵
    1. Raymond WD,
    2. Preen DB,
    3. Keen HI,
    4. Inderjeeth CA,
    5. Nossent JC.
    Cancer development in patients hospitalized with systemic lupus erythematosus: a population-level data linkage study. Int J Rheum Dis 2023;26:1557-70.
    OpenUrlPubMed
  27. 27.↵
    1. Ladouceur A,
    2. Tessier-Cloutier B,
    3. Clarke AE, et al.
    Cancer and systemic lupus erythematosus. Rheum Dis Clin North Am 2020;46:533-50.
    OpenUrlPubMed
  28. 28.↵
    1. Kósa F,
    2. Kunovszki P,
    3. Gimesi-Országh J, et al.
    High risk of depression, anxiety, and an unfavorable complex comorbidity profile is associated with SLE: a nationwide patient-level study. Arthritis Res Ther 2022;24:116.
    OpenUrlCrossRefPubMed
  29. 29.↵
    1. Carrión-Barberà I,
    2. Salman-Monte TC,
    3. Vílchez-Oya F,
    4. Monfort J.
    Neuropsychiatric involvement in systemic lupus erythematosus: a review. Autoimmun Rev 2021;20:102780.
    OpenUrlPubMed
  30. 30.↵
    1. Dietz B,
    2. Katz P,
    3. Dall’Era M, et al.
    Major depression and adverse patient-reported outcomes in systemic lupus erythematosus: results from a prospective longitudinal cohort. Arthritis Care Res 2021;73:48-54.
    OpenUrl
  31. 31.↵
    1. Julian LJ,
    2. Tonner C,
    3. Yelin E, et al.
    Cardiovascular and disease-related predictors of depression in systemic lupus erythematosus. Arthritis Care Res 2011;63:542-9.
    OpenUrlCrossRef
  32. 32.
    1. Dehghan A,
    2. Soltani H,
    3. Faezi ST, et al.
    Depression, anxiety, and quality of life in patients with systemic lupus erythematosus. Reumatologia 2023;61:368-74.
    OpenUrlPubMed
  33. 33.↵
    1. Bergmans RS,
    2. Loewenstein E,
    3. Aboul-Hassan D, et al.
    Social determinants of depression in systemic lupus erythematosus: a systematic scoping review. Lupus 2023;32:23-41.
    OpenUrlPubMed
  34. 34.↵
    1. Liu X,
    2. Jia X,
    3. Wang X,
    4. Wei YB,
    5. Liu JJ.
    Mental health conditions in patients with systemic lupus erythematosus: a systematic review and meta-analysis. Rheumatology 2024;63:3234-42.
    OpenUrlPubMed
  35. 35.↵
    1. van der Goes MC,
    2. Strehl C,
    3. Buttgereit F,
    4. Bijlsma JW,
    5. Jacobs JW.
    Can adverse effects of glucocorticoid therapy be prevented and treated? Expert Opin Pharmacother 2016;17:2129-33.
    OpenUrlCrossRefPubMed
  36. 36.
    1. Humphrey MB,
    2. Russell L,
    3. Danila MI, et al.
    2022 American College of Rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheumatol 2023;75:2088-102.
    OpenUrlPubMed
  37. 37.↵
    1. Woods CP,
    2. Hazlehurst JM,
    3. Tomlinson JW.
    Glucocorticoids and non-alcoholic fatty liver disease. J Steroid Biochem Mol Biol 2015;154:94-103.
    OpenUrlCrossRefPubMed
  38. 38.↵
    1. Li JX,
    2. Cummins CL.
    Fresh insights into glucocorticoid-induced diabetes mellitus and new therapeutic directions. Nat Rev Endocrinol 2022;18:540-57.
    OpenUrlCrossRefPubMed
  39. 39.↵
    1. Faurschou M,
    2. Ahlström MG,
    3. Lindhardsen J,
    4. Obel N,
    5. Baslund B.
    Risk of diabetes mellitus among patients diagnosed with giant cell arteritis or granulomatosis with polyangiitis: comparison with the general population. J Rheumatol 2017;44:78-83.
    OpenUrlAbstract/FREE Full Text
  40. 40.↵
    1. Johnson SR,
    2. Gladman DD,
    3. Brunner HI, et al.
    Evaluating the construct of damage in systemic lupus erythematosus. Arthritis Care Res 2023;75:998-1006.
    OpenUrl
  41. 41.↵
    1. Gomez A,
    2. Parodis I,
    3. Saleh M,
    4. Simard JF,
    5. Sjöwall C,
    6. Arkema EV.
    Development and evaluation of a register-based organ damage index in systemic lupus erythematosus: a nationwide, population-based study from Sweden. Lupus Sci Med 2025;12:e001403.
    OpenUrlAbstract/FREE Full Text
  42. 42.↵
    1. Tektonidou MG,
    2. Lewandowski LB,
    3. Hu J,
    4. Dasgupta A,
    5. Ward MM.
    Survival in adults and children with systemic lupus erythematosus: a systematic review and Bayesian meta-analysis of studies from 1950 to 2016. Ann Rheum Dis 2017;76:2009-16.
    OpenUrlAbstract/FREE Full Text
  43. 43.↵
    1. Bultink IEM,
    2. de Vries F,
    3. van Vollenhoven RF,
    4. Lalmohamed A.
    Mortality, causes of death and influence of medication use in patients with systemic lupus erythematosus vs matched controls. Rheumatology 2021;60:207-16.
    OpenUrlCrossRefPubMed
  44. 44.↵
    1. Zen M,
    2. Salmaso L,
    3. Barbiellini Amidei C, et al.
    Mortality and causes of death in systemic lupus erythematosus over the last decade: data from a large population-based study. Eur J Intern Med 2023; 112:45-51.
    OpenUrlPubMed
  45. 45.↵
    1. Lee YH,
    2. Choi SJ,
    3. Ji JD,
    4. Song GG.
    Overall and cause-specific mortality in systemic lupus erythematosus: an updated meta-analysis. Lupus 2016;25:727-34.
    OpenUrlCrossRefPubMed
  46. 46.↵
    1. Luo W,
    2. Farinha F,
    3. Isenberg DA,
    4. Rahman A.
    Survival analysis of mortality and development of lupus nephritis in patients with systemic lupus erythematosus up to 40 years of follow-up. Rheumatology 2022;62:200-8.
    OpenUrlPubMed
  47. 47.↵
    1. Faurschou M,
    2. Dreyer L,
    3. Kamper AL,
    4. Starklint H,
    5. Jacobsen S.
    Long-term mortality and renal outcome in a cohort of 100 patients with lupus nephritis. Arthritis Care Res 2010;62:873-80.
    OpenUrlCrossRef
  48. 48.↵
    1. Kasitanon N,
    2. Magder LS,
    3. Petri M.
    Predictors of survival in systemic lupus erythematosus. Med 2006;85:147-56.
    OpenUrl
  49. 49.↵
    1. Urowitz MB,
    2. Gladman DD,
    3. Ibañez D, et al.
    Evolution of disease burden over five years in a multicenter inception systemic lupus erythematosus cohort. Arthritis Care Res 2012;64:132-7.
    OpenUrlCrossRef
  50. 50.↵
    1. Murimi-Worstell IB,
    2. Lin DH,
    3. Nab H, et al.
    Association between organ damage and mortality in systemic lupus erythematosus: a systematic review and meta-analysis. BMJ Open 2020;10:e031850.
    OpenUrlAbstract/FREE Full Text
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

 Request Permissions

Bookmark this article

Jump to section

Keywords

COMORBIDITY
INCIDENCE
MORTALITY
SYSTEMIC LUPUS ERYTHEMATOSUS

Keywords